SHEN-26

N/A

Report date: 2023/11/30 16:45:17
NME

Base Information

Drug NameSHEN-26
Drug Alias NameSHEN-26ATV-014
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionRNA-directed RNA polymerase inhibitors
TargetsRNA-directed RNA polymerase
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesShenzhen Antaiwei Biomedical Co LtdShandong Kexing Bio-Products Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesShandong Kexing Bio-Products Co LtdShenzhen Kexing Pharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsCoronavirus Disease 2019 (COVID-19)
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A